Medidata Debuts Protocol Optimization at ASCO, Leveraging AI to Transform the Study Experience
New solution improves protocol design, reduces patient- and site-burden, accelerates recruitment, and delivers increased efficiencies for clinical trials
SINGAPORE, June 2, 2025 /PRNewswire/ -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced the launch of Medidata Protocol Optimization, part of the Medidata Study Experience which is available on the Medidata Platform. Medidata is showcasing this novel solution at the American Society of Clinical Oncology (ASCO) 2025 conference, which will be held from May 30–June 3, 2025 in Chicago.
Medidata Protocol Optimization, a flagship component of the unified Study Experience, transforms trial design and execution by leveraging AI-driven predictive modeling, digital protocols, and industry-leading aggregated data to simulate trial performance. This solution has the ability to predict the impact on patient burden, site performance, and costs, well in advance of the First Patient In (FPI) resulting in research teams gaining critical foresight into the potential challenges. This approach significantly decreases costly amendments and enrollment delays, leading to smoother and lower cost trials.
"Oncology trials are some of the most intricate and demanding in clinical research, often leading to more changes during the study than any other therapeutic area," said Dan Braga, senior vice president, Study Experience, Medidata. "Because of this complexity, we wanted to introduce Protocol Optimization at ASCO to give researchers a deeper look into how balancing scientific intention and practical execution can bring treatments to the market more effectively."
To learn more about Protocol Optimization, please visit here.
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata's seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes' 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: www.3ds.com.
Logo - https://mma.prnewswire.com/media/2699901/Medidata_Logo.jpg
Share this article